In addition to a gene signature associated with stemness and EMT we were able to identify tumor markers that are used in clinical trials, such as mucin 1 (MUC1; used to monitor metastasis in patients) and members of the carcinoembryonic antigen (CEA) related cell adhesion molecules (CEACAM) family. Here, MUC1 is linked to neoplasm.